ATE380875T1 - Chimäre proteine zur vermeidung der komplementaktivierung - Google Patents

Chimäre proteine zur vermeidung der komplementaktivierung

Info

Publication number
ATE380875T1
ATE380875T1 AT94931763T AT94931763T ATE380875T1 AT E380875 T1 ATE380875 T1 AT E380875T1 AT 94931763 T AT94931763 T AT 94931763T AT 94931763 T AT94931763 T AT 94931763T AT E380875 T1 ATE380875 T1 AT E380875T1
Authority
AT
Austria
Prior art keywords
chimeric proteins
complement activation
avoid complement
avoid
polypeptide
Prior art date
Application number
AT94931763T
Other languages
English (en)
Inventor
Jone-Long Ko
Paul J Higgins
C Grace Yeh
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE380875T1 publication Critical patent/ATE380875T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94931763T 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung ATE380875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation

Publications (1)

Publication Number Publication Date
ATE380875T1 true ATE380875T1 (de) 2007-12-15

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931763T ATE380875T1 (de) 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung

Country Status (9)

Country Link
US (2) US5679546A (de)
EP (1) EP0723555B1 (de)
JP (2) JP3860605B2 (de)
CN (1) CN1057097C (de)
AT (1) ATE380875T1 (de)
AU (1) AU697167B2 (de)
CA (1) CA2172610A1 (de)
DE (1) DE69435049D1 (de)
WO (1) WO1995008570A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
ATE286743T1 (de) * 1997-10-31 2005-01-15 Us Army Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
CN101298481A (zh) * 1998-02-20 2008-11-05 吉宁特有限公司 补体活化的抑制剂
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CA2389633A1 (en) * 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
US6534058B2 (en) 2000-10-10 2003-03-18 Tanox, Inc. Anti-C5 monoclonal antibodies
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
JP4476623B2 (ja) * 2001-06-08 2010-06-09 ノバルティス アーゲー インスリン産生細胞移植片拒絶の処置または予防
US20060153839A1 (en) * 2002-09-16 2006-07-13 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US8124097B2 (en) 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
ATE500836T1 (de) 2004-03-31 2011-03-15 The Feinstein Inst Medical Res Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
JP5707024B2 (ja) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
EP2044111B1 (de) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting des komplement-faktors h zur krankheitsbehandlung
SI2097455T1 (sl) * 2006-11-02 2015-03-31 Genentech, Inc. Humanizirana protitelesa proti faktorju tipa d
US20100120665A1 (en) * 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
EP2565207A3 (de) * 2007-03-14 2013-06-12 Alexion Cambridge Corporation Humanisierte Anti-Faktor-B-Antikörper
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6244350B2 (ja) * 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
EP3234598B1 (de) 2014-12-18 2019-11-06 F.Hoffmann-La Roche Ag Assay und verfahren zur bestimmung cdc-entlockender antikörper
US10988519B2 (en) 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10640540B2 (en) 2015-12-23 2020-05-05 Greenovation Biotech Gmbh Polypeptides for inhibiting complement activation
JP7068203B2 (ja) 2016-06-28 2022-05-16 ウニベルジテート ウルム 補体阻害剤及びその使用
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20220195012A1 (en) * 2019-04-13 2022-06-23 National Centre For Cell Science Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
DK0489116T3 (da) * 1989-08-22 1994-05-02 Immunex Corp Fusionsproteiner omfattende GM-CSF og IL-3
AU7328891A (en) * 1990-01-26 1991-08-21 Biogen, Inc. C4 binding protein fusion proteins
EP0512733A2 (de) * 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
JPH09502985A (ja) 1997-03-25
EP0723555B1 (de) 2007-12-12
EP0723555A1 (de) 1996-07-31
US5679546A (en) 1997-10-21
WO1995008570A1 (en) 1995-03-30
JP3860605B2 (ja) 2006-12-20
EP0723555A4 (de) 1999-04-28
AU8071994A (en) 1995-04-10
AU697167B2 (en) 1998-10-01
JP2005041882A (ja) 2005-02-17
CN1138863A (zh) 1996-12-25
CN1057097C (zh) 2000-10-04
CA2172610A1 (en) 1995-03-30
US5851528A (en) 1998-12-22
DE69435049D1 (de) 2008-01-24

Similar Documents

Publication Publication Date Title
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
NO965362L (no) Syntetiske lederpeptidsekvenser
NO971875L (no) Cathepsin 02 protease
TW430669B (en) A hybrid toxin fragment and their use
ATE189475T1 (de) Wachstums-differenzierungsfaktor der tgf-b familie
ATE226634T1 (de) Fibronektin bindendes protein
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE389023T1 (de) Kontrolle der schotendehiszenz
EP0422125A4 (en) Platelet blocking peptides
ES2058479T3 (es) Compuestos peptidicos.
DE69634077D1 (de) Haemophilus adhäsionsproteinen
PT635025E (pt) Processo para preparar proteinas modificadas
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
DK0826054T3 (da) Ekspression af glycosyltransferase i Aspergillus
EP0714982A3 (de) Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
DE69033553D1 (de) Rekombinante herstellung von laktoperoxidase
DE68917536D1 (de) Methode zur Reduktion von aromatischen Amino-Gruppen.
DK0858465T3 (da) Protein med antitumorvirkning.
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties